NCT06668181

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 2 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Conditions

• Enthesitis-related Arthritis
• Juvenile Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	Bimekizumab	Bimekizumab will be administered at pre-specified timepoints.

Timeline

• Start date: 2025-03-11
• Primary completion: 2028-04-12
• Completion: 2030-07-31
• First posted: 2024-10-31
• Last updated: 2026-02-27

Locations

23 sites across 6 countries: Canada, France, Germany, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study